| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | Chief Business Officer | Restricted Stock Units | 148K | $155K | $1.05 | Feb 1, 2024 | Direct |
| Anika Therapeutics, Inc. | EVP Business Development | Common Stock | 5.59K | $104K | $18.63 | Jul 8, 2021 | Direct |
| Anika Therapeutics, Inc. | EVP Business Development | Restricted Stock Unit | 3K | $77.4K | $25.79 | Jul 8, 2021 | Direct |
| Aclaris Therapeutics, Inc. | Chief Business Officer | Common Stock | 34K | $40.8K | $1.20 | Feb 1, 2024 | Direct |
| Aclaris Therapeutics, Inc. | Chief Business Officer | Employee Stock Option (Right to Buy) | 207K | Feb 1, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | Feb 1, 2024 | 9 | -$7.71K | 4 | Feb 5, 2024 | Chief Business Officer |
| ACRS | Aclaris Therapeutics, Inc. | Aug 28, 2023 | 1 | $100K | 4 | Aug 28, 2023 | Chief Business Officer |
| ACRS | Aclaris Therapeutics, Inc. | Feb 8, 2023 | 1 | -$59.3K | 4 | Feb 10, 2023 | Chief Business Officer |
| ACRS | Aclaris Therapeutics, Inc. | Feb 1, 2023 | 4 | $0 | 4 | Feb 3, 2023 | Chief Business Officer |
| ACRS | Aclaris Therapeutics, Inc. | Feb 1, 2022 | 2 | $0 | 4 | Feb 1, 2022 | Chief Business Officer |
| ACRS | Aclaris Therapeutics, Inc. | Jan 31, 2022 | 0 | $0 | 3 | Feb 1, 2022 | Chief Business Officer |
| ANIK | Anika Therapeutics, Inc. | Jul 8, 2021 | 3 | -$31.6K | 4 | Jul 12, 2021 | EVP Business Development |